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Depression is a highly prevalent disorder in Europe and is
often managed in primary care [24]. Antidepressant drugs
are effective in the treatment of depression and are the most
widely used form of treatment [7,8]. Over the past decade,
there has been an increase in the number and types of antide-
pressants available. They have a wide range of mechanisms of
action but are primarily targeted at modulating the function of
the neurotransmitters serotonin and/or norepinephrine and/or
dopamine.
For many years, tricyclic and tetracyclic antidepressants
(TCAs) were the first-line treatment choice for depression in
Europe, but recent studies indicate that selective serotonin re-
uptake inhibitors (SSRIs) are now the initial choice of antide-
pressant in many countries and are the most commonly
prescribed group of antidepressant drugs [16,18,20,23,32].
However, surveys have shown that there are differences in
the prescribing of antidepressants between European countries
[12,30].
Systematic reviews, meta-analyses and evidence-based
treatment guidelines have found that different antidepressants
have comparable efficacy in the majority of patients with de-
pression seen in primary care or outpatient psychiatric settings
[6,7,17,19,33]. However, for example, SSRIs are generally
better tolerated than TCAs and are less likely to be discontin-
ued due to side effects [3,6,19,22]. Early discontinuation of
antidepressant therapy may increase the risk of relapse or re-
currence of depression [10].
Numerous factors influence the choice of antidepressant
drug prescribed by physicians, including physician and patient
characteristics; e.g. physician speciality and country of prac-
tice, severity of depression, and previous depressive episodes
[28,35,38]. Current practice guidelines recommend that physi-
cians should choose an antidepressant drug based on past ex-
perience of treatment, side effects, patient preference and cost
[2,4,7,22]. The presence of comorbid psychiatric or general
physical conditions may also influence the choice [6].
The Factors Influencing Depression Endpoints Research
(FINDER) study is a pan-European study designed to increase
understanding of the factors that influence health-related qual-
ity of life (HRQoL) outcomes for patients with a depressive ep-
isode in routine primary and specialist care settings [15]. The
study design and characteristics of the population at baseline
are described in a companion paper. The objectives of the pres-
ent analysis are to determine the current prescribing patterns of
antidepressants in 12 European countries and to examine how
physician and patient characteristics influence the selection of
an initial antidepressant in the FINDER study population.2. Methods2.1. Study design and subjectsFINDER is a 6-month, observational, multicentre study
conducted in 12 European countries: Austria, Belgium,
France, Germany, Ireland, Italy, The Netherlands, Norway,
Portugal, Sweden, Switzerland and the UK. The study design
and methods have been reported in detail elsewhere [15].
Briefly, the participating investigators were primary care phy-
sicians (PCPs) or specialists (mostly psychiatrists). Eligible
patients were enrolled consecutively within each participating
centre from May 2004 to September 2005. The study popula-
tion comprised adult patients (aged 18 years) presenting
within the normal course of care with a clinical diagnosis of
depression and whose physician had already decided to com-
mence antidepressant treatment for a first episode or a new re-
current episode of depression. The study was approved in all
countries according to local requirements for ethics and/or
regulatory approvals for observational studies, and all patients
gave written informed consent.
Data were collected at baseline (the routine visit at which
the patient agreed to enter the study) and at 3 and 6 months
post-baseline during visits that were part of the routine clinical
care of the patient. Only baseline data are presented in this
report.2.2. Data collectedThe data recorded at baseline included patient socio-demo-
graphics, psychiatric history such as the number of previous
episodes of depression and the occurrence of any specified
psychiatric illnesses in the previous 24 months, the duration
of the current depressive episode and the presence of comorbid
chronic physical conditions and comorbid functional syn-
dromes from a specific list.
Information on the use of antidepressants in the previous 24
months was collected as well as the type and dose of antidepres-
sant(s) prescribed at the baseline visit. For the purpose of the
current analyses, antidepressant medications were grouped as
follows: SSRIs (citalopram, escitalopram, fluoxetine, fluvox-
amine, paroxetine, sertraline); serotonin and norepinephrine
reuptake inhibitors (SNRIs; duloxetine, milnacipran, venlafax-
ine); TCAs (amoxapine, amitriptyline, clomipramine, desipra-
mine, dothiepin/dosulepin, doxepin, imipramine, lofepramine,
maprotiline, mianserin, nortriptyline, opipramol, trimipr-
amine); others (including herbal remedies [hypericum, St.
John’s wort], flupentixol, lithium, monoamine oxidase inhibi-
tors [MAOIs; moclobemide, phenelzine, tranylcypromine],
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and combinations of antidepressants from more than one of
the above groups.
The patient-rated Hospital Anxiety and Depression Scale
(HADS) [36] was completed at baseline: this consists of seven
items for depression (subscale HADS-D) and seven items for
anxiety (subscale HADS-A). Patients also rated their overall
health state on the day of assessment using the European Qual-
ity of Life-5 Dimensions (EQ-5D) visual analogue scale
(VAS), which ranges from 0 (worst imaginable health state)
to 100 (best imaginable health state) [9]. Overall pain severity
was rated by patients using a VAS (0e100 mm), with patients
scoring 30 mm considered to have moderate/severe pain.2.3. Statistical analysisData describing the study population and prescribing pat-
tern of antidepressants are presented as means, standard devi-
ations (SD), frequencies or percentages, as appropriate.
To examine factors associated with the choice of the antide-
pressant prescribed at baseline, the following binary outcomes
were modelled using generalised estimating equations (GEE):
(1) patients prescribed SSRIs alone at baseline (yes vs. no); (2)
patients prescribed SNRIs alone at baseline (yes vs. no); (3)
patients prescribed more than one antidepressant at baseline
vs. only one antidepressant; and (4) for Germany only, patients
prescribed TCAs alone at baseline (yes vs. no). The first two
outcomes were chosen based on the prescribing frequency of
the groups (i.e. SSRIs and SNRIs were the most and second
most prescribed AD groups in FINDER), the third outcome
was chosen to investigate factors associated with the initiation
of more than one antidepressant, and the last outcome was
chosen because more than a quarter of FINDER patients in
Germany were prescribed TCAs (see Fig. 1).
The GEE analysis method was chosen because it is ex-
pected that for each investigator, the choice of prescription
for one patient is not likely to be independent of his choice
for another of his patients, unlike in a conventional logistic0%
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Fig. 1. Prescribing of antidepressant group by country (foregression analysis in which a crucial assumption is that all
observations (patients) are independent. We expect the choice
of drug group prescribed to be influenced by characteristics of
both the investigator and the patient. In the GEE analysis, pa-
tients are ‘‘clustered’’ within investigator sites, which means
that observations are independent between clusters (investiga-
tors) but correlated within clusters. An ‘‘exchangeable’’ corre-
lation matrix was used, which assumes that the correlation
between each pair of patients seen by an investigator is the
same, regardless of the order in which they were seen. This
seems a reasonable assumption because of the relatively short
period of time during which an investigator would have been
enrolling patients into the study.
Independent variables used in the initial model for the first
three outcomes were as follows: (1) investigator-related vari-
ables: age, gender, location of practice, and speciality; (2)
patient-related variables: age, gender, body mass index, educa-
tion level, occupational status, smoking, number of dependants,
marital status, number of previous episodes of depression, anti-
depressant use in the previous 24 months, previous anxiety and/
or panic disorder, total number of current physical conditions
and functional syndromes, duration of current depressive epi-
sode, pain (VAS overall pain score>30), EQ-5D VAS, severity
of depression (HADS-D) and severity of anxiety (HADS-A);
and (3) country.
For analysis of TCAs alone at baseline, the country was
omitted since only German patients/investigators were in-
cluded in the model.
Models were built using stepwise methods to include only
those independent variables that were statistically significantly
associated ( p 0.05) with the outcome variable. The effect of
adding other variables that were of borderline significance was
investigated in the models. To be eligible for inclusion in the
models, physicians and patients must have a non-missing re-
sult for the outcome variable and all of the independent vari-
ables. Data were analysed using SAS version 8.2 and are
presented as odds ratios (OR) and 95% confidence intervals
(CIs) for each of the comparisons.Italy Netherlands Sweden Switzerland UK
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A total of 3515 patients were enrolled in the study and data
from 3468 patients (98.7%) were eligible for analysis. Forty
seven patients were not eligible for analysis due to no prescrip-
tion of antidepressants (n¼ 42) ormissing age (n¼ 5).Most pa-
tients in the analysis sample were from Germany (n¼ 649), UK
(n¼ 608), France (n¼ 606) and Italy (n¼ 513), with fewer
than 50 patients each from Portugal (n¼ 48) and Norway
(n¼ 40). Due to the small sample size, the results for patients
in Portugal and Norway will not be presented individually or
discussed further.
Across the 12 participating European countries, eligible pa-
tients were enrolled by a total of 437 investigators (211 PCPs
[48.3%] and 226 specialists [51.7%]), although the type of in-
vestigator varied by country (Fig. 1). The majority of investi-
gators (62.7%) were in an urban practice setting. The mean
age of the investigators was 50.1 years (SD 6.8) and 76.4%
were male.
The baseline characteristics of the patients in the FINDER
study have been reported elsewhere [15]. In short, HRQoL
was largely impaired at enrolment when compared to popula-
tion-based standards. The baseline values of all patient-related
independent variables included in the current analyses, includ-
ing scores for HRQoL and depression, are summarised in
Table 1.Table 1
Patient socio-demographics, psychiatric history and baseline findings in the
FINDER study population (n¼ 3468)
Variable
Socio-demographics
Age, years 46.8 (14.7)
Gender, % female 68.2
BMI, kg/m2 25.5 (5.2)
No or mandatory level of education, % patients 52.3
Unemployed, % patients 13.7
In paid work, % patients 50.1
Smokers, % patients 32.3
Number of dependants 1.1 (1.3)
Marital status, % married/domestic partner 58.6
Psychiatric history (in the last 24 months)
Number of previous episodes of depressiona 1.8 (1.4)
Anxiety/panic disorder, % patients 51.1
Antidepressant use, % patients 38.2
Medical history
Chronic physical condition present, % patients 42.5
Current functional syndrome present, % patients 39.9
Pain (moderate/severe), % patients 56.2
Baseline findings
EQ-5D VAS score (range 0e100) 44.8 (20.4)
HADS-D score (range 0e21) 12.3 (4.5)
HADS-A score (range 0e21) 13.0 (4.0)
Duration of current depressive episode, weeks 13.6 (16.5)
Data are presented as mean (SD) unless indicated otherwise.
For abbreviations see text.
a For only those patients with 1 previous depressive episode in the last 24
months.3.1. Prescribing patterns of antidepressantsFig. 1 shows that SSRIs were the most commonly pre-
scribed antidepressant at baseline (63.3% of all patients)
followed by SNRIs (13.6% of all patients). There was consid-
erable variation between countries in the prescribing of differ-
ent groups of antidepressants: the percentage of patients
prescribed SSRIs ranged from 31.7% (Germany) to 81.5%
(France), and that of SNRIs ranged from 6.1% (Austria) to
25.5% (The Netherlands). TCAs were prescribed for 26.5%
patients in Germany, but across the other countries were pre-
scribed for between only 1.5% patients (Sweden and The
Netherlands) and 8.6% patients (Austria). Combinations of
more than one antidepressant were prescribed most frequently
in Austria (24.5% patients) and not at all in Ireland or The
Netherlands.
The mean and median prescribed doses of the most fre-
quently recorded antidepressants are summarised by physician
speciality in Table 2. Of note, the mean doses of amitriptyline
(55.6 mg/day) and doxepin (47.8 mg/day) were below the cur-
rently recommended starting dose (75 mg/day) for these
TCAs. Primary care physicians prescribed lower mean doses
than specialists for amitriptyline, sertraline and venlafaxine,
but higher mean doses for duloxetine and trazodone.3.2. Factors associated with initial antidepressant choice
3.2.1. Patients prescribed SSRIs alone
The variables significantly associated with being prescribed
SSRIs alone at baseline are summarised in Table 3. The factor
with the strongest association was whether or not the patient
had had any previous antidepressant use in the 24 months be-
fore the study; those who had previously taken an antidepres-
sant were 0.64 times less likely to be prescribed a SSRI than
those who had not. Older investigators, older patients and
smokers were associated with a decreased likelihood of
a SSRI being prescribed, whereas patients with further educa-
tion were more likely to receive a SSRI.
3.2.2. Patients prescribed SNRIs alone
Two variables were significantly associated with a SNRI
being prescribed at baseline (n¼ 3431): (1) female physicians
were more likely to prescribe a SNRI than male physicians
(OR 1.77; 95% CI 1.27, 2.48), and (2) patients who had pre-
vious antidepressant use were more likely to receive a SNRI
than those who had not used an antidepressant in the previous
24 months (OR 1.49; 95% CI 1.18, 1.88). Additionally, some
of the country comparisons to the UK were statistically signif-
icant, meaning that in those countries SNRI prescribing was
more likely than in the UK as reference country (The Nether-
lands OR 3.64, 95% CI 1.92, 6.89; Germany OR 1.76, 95% CI
1.04, 2.98; Italy OR 1.82, 95% CI 1.03, 3.23).
3.2.3. Patients prescribed more than one antidepressant vs.
a single antidepressant
In two countries (Ireland and The Netherlands), none of the
patients were prescribed more than one antidepressant. Since
Table 2
Doses of most frequently prescribed antidepressants by speciality at enrolment
All (n¼ 3468) Primary care physicians (n¼ 1818) Specialists (n¼ 1650)
Number of
patients
Mean (SD)/median
dose (mg)
Number of
patients
Mean (SD)/median
dose (mg)
Number of
patients
Mean (SD)/median
dose (mg)
Amitriptyline 113 55.6 (39.2)/50.0 54 49.1 (38.5)/43.8 59 61.5 (39.1)/50.0
Citalopram 521 20.0 (7.9)/20.0 274 19.2 (6.3)/20.0 247 21.0 (9.2)/20.0
Doxepin 70 47.8 (33.6)/50.0 51 47.1 (36.7)/25.0 19 49.7 (23.9)/50.0
Duloxetine 103 49.5 (16.6)/60.0 38 56.8 (11.6)/60.0 65 45.2 (17.7)/30.0
Escitalopram 426 11.2 (4.5)/10.0 168 10.7 (3.5)/10.0 258 11.5 (5.0)/10.0
Fluoxetine 686 20.7 (7.5)/20.0 428 20.5 (3.7)/20.0 258 21.0 (11.3)/20.0
Mirtazapine 253 26.5 (9.1)/30.0 76 25.0 (8.1)/30.0 177 27.2 (9.4)/30.0
Paroxetine 337 21.5 (7.1)/20.0 162 21.5 (6.9)/20.0 175 21.5 (7.4)/20.0
Sertraline 323 58.1 (25.5)/50.0 100 51.5 (16.1)/50.0 223 61.1 (28.3)/50.0
Trazodone 78 88.6 (43.2)/100.0 10 117.5 (29.0)/100.0 68 84.3 (43.4)/75.0
Venlafaxine 391 95.6 (44.3)/75.0 180 80.7 (30.6)/75.0 211 108.2 (49.9)/75.0
Includes all antidepressants prescribed to at least 50 patients.
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two analyses are presented, one excluding these two countries
and the other pooling Ireland with the UK and The Nether-
lands with Belgium. In the second analysis, the reference
country was UK/Ireland.
Table 4 lists the variables significantly associated with be-
ing prescribed more than one antidepressant at baseline in
both analyses. Previous treatment with an antidepressant was
the covariate most strongly associated with receiving more
than one antidepressant at baseline. A one-point increase in
the HADS-D score was associated with an increased likeli-
hood of being prescribed a combination of antidepressants
by a factor of 1.07. Physician age was also associated with
an increased likelihood of being prescribed a combination of
antidepressants by a factor of 1.22 for every additional 5 years
of age (model 2).3.2.4. Patients prescribed TCAs alone (in Germany)
Table 5 summarises the variables significantly associated
with being prescribed TCAs alone in Germany. The most in-
fluential factor was physician gender, with female physicians
0.20 times less likely to prescribe TCAs than male physicians.
Also significant were the total number of current physical con-
ditions and functional syndromes, with the odds of being pre-
scribed TCAs increased by a factor of 1.13 for each additionalTable 3
Variables significantly associated with being prescribed SSRIs at enrolment
(GEE analysis), n¼ 3357
Chi-
square
p-value Odds
ratio (OR)
95% CI
Any previous
antidepressant (yes vs. no)
25.4 <0.0001 0.64 0.54, 0.76
Physician age per 5 years 7.6 0.006 0.88 0.80, 0.96
Patient age per 5 years 10.4 0.001 0.95 0.93, 0.98
Smoking (yes vs. no) 5.6 0.018 0.82 0.69, 0.97
Education (further vs.
no/mandatory)
5.7 0.017 1.22 1.04, 1.44
Country was also statistically significant in the model with significant differ-
ences from the UK observed for all countries apart from France and Ireland.condition. Finally, German PCPs were 2.30 times more likely
to prescribe TCAs than specialists.4. Discussion4.1. Differences among countriesIn each of the 12 countries taking part in the FINDER
study, SSRIs were the most common group of antidepressant
prescribed for patients with a first episode of depression or
a new episode of recurrent depression. TCAs were used in
just over one-quarter of the patients in Germany and combina-
tions of antidepressants were prescribed for approximately
one-quarter of the patients in Austria. In the other countries
examined individually, SNRIs were the second most common
group of antidepressants prescribed. Several physician and pa-
tient characteristics influenced the choice of antidepressant
prescribed, but the factor most consistently and strongly asso-
ciated with antidepressant selection was previous antidepres-
sant use in the 24 months before the study.
Since SSRIs tend to be the first choice antidepressant, those
patients who have taken an antidepressant previously and are
entering the FINDER study with a recurrent episode of depres-
sion are more likely to be prescribed a SNRI (OR> 1) than
patients who had not used antidepressants in the previous 24
months.
The finding of SSRIs being the predominant antidepressant
group prescribed is consistent with previous reports in Euro-
pean and other countries [16,18,21,23,29,32]. Although SSRIs
are considered no more effective than other classes of antide-
pressants, they are recommended because they can be admin-
istered once daily, require less dose-titration than TCAs, and
are associated with fewer side effects and lower cardiovascular
toxicity in overdose than TCAs [7,25].
There was considerable variation in the types of antidepres-
sant prescribed across the different countries taking part in the
study. This may be due in part to the differing availability and
prices of antidepressants aswell as recommendations in national
guidelines, reimbursement status and promotional activities in
Table 4
Variables significantly associated with being prescribed combination antidepressants (GEE analysis), n¼ 3104 (excluding Ireland and The Netherlands; model 1)
and n¼ 3360 (including all countries; model 2)
Model 1 Model 2
Chi-square p-value Odds
ratio (OR)
95% CI Chi-square p-value Odds
ratio (OR)
95% CI
Any previous antidepressant (yes vs. no) 31.0 <0.0001 2.71 1.91, 3.84 32.7 <0.0001 2.78 1.96, 3.96
HADS-D 7.4 0.006 1.07 1.02, 1.13 7.5 0.006 1.07 1.02, 1.13
Physician age per 5 years 5.1 0.024 1.23 1.03, 1.48 4.3 0.038 1.22 1.01, 1.48
All of the country comparisons to the UK (model 1) or UK/Ireland (model 2) are statistically significant apart from Sweden.
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to account for these known variations, and thus all findings
related to the physician and/or patient characteristics were ad-
justed for those unmeasured country-specific factors. Differ-
ences in the types of antidepressant prescribed will also be
influenced by the availability and use of other forms of treatment
in these countries, such as psychological therapy, as well as the
relative proportions of PCPs and specialists taking part in the
FINDER study.
Our findings of a high use of TCAs in Germany are sup-
ported by prescribing patterns of antidepressants in two recent
studies, one of children and adolescents in Germany [13] and
one of outpatients within a German state based on claims data
[31]. SNRIs are available in all the countries taking part in
FINDER, but the relatively low use of SNRIs in the UK
(9.2%) may reflect the high proportion of PCPs in the study
and UK guideline recommendations that venlafaxine should
only be initiated and managed by specialists [22].
Antidepressant combinations are frequently used in clinical
practice [11]. Interestingly, in the FINDER study, the use of
combinations of antidepressants was much more common in
Austria (24.5%) than in any of the other countries examined
individually (each less than 7%). This may be due to the char-
acteristics of the patient population in these countries. On the
other hand, all investigators in Austria were specialists and
may treat depression more aggressively than PCPs to achieve
full remission [1]. Moreover, it has been recommended in the
UK, for example, that antidepressant combinations should
only be initiated under specialist supervision [22].
Most antidepressants were used at their recommended
doses. Notable exceptions were amitriptyline and doxepin
(both TCAs), which were both initiated at mean daily doses
below the recommended dose, although the evidence baseTable 5
Variables significantly associated with being prescribed TCA(s) in Germany
(GEE analysis), n¼ 641
Chi-
square
p-value Odds
ratio (OR)
95% CI
Physician gender
(female vs. male)
11.4 0.001 0.20 0.08, 0.51
Physician speciality
(PCP vs. specialist)
4.8 0.028 2.30 1.09, 4.84
Total number of current physical
conditions and functional
syndromes
9.3 0.002 1.13 1.04, 1.22
PCP, primary care physician.for the currently recommended doses is not well established
[14]. Although recent meta-analyses have shown that low-
dose TCAs (100 mg/day) are effective for the treatment of
depression [5,14], there remain concerns that TCAs are often
prescribed at less than adequate doses. Prescription of TCAs at
low doses, especially by PCPs, may be related to concerns
about the side effects associated with TCAs. In addition, the
mean dose of duloxetine prescribed by specialists was below
the recommended daily dose of 60 mg, which may indicate
their preference for up-titration of patients to the recommen-
ded dose [34].4.2. Factors influencing prescribing patternsPractice guidelines recommend that physicians should
choose an antidepressant drug based on the past experience
of treatment, side effects, patient preference and cost
[2,7,22]. We found that previous antidepressant use was con-
sistently and most strongly associated with the selection of
the antidepressant. This suggests that past experience and out-
comes of previous treatments do indeed influence the choice of
antidepressant drug. Our findings are consistent with those of
the survey by Zimmerman et al. [38], where prior treatment
history was an important factor influencing antidepressant
medication choice by psychiatrists. Rush et al. [26] investi-
gated switching antidepressants due to intolerability or not
achieving remission with initial treatment with citalopram.
In this particular context, remission rates were not dependent
on the class of the new antidepressant prescribed. We will
be investigating switching patterns and the associated out-
comes during the FINDER 6-month study period in further
analyses of the longitudinal data.
Physician age and gender were important factors influenc-
ing antidepressant selection in some models. In particular,
physician age was significant for SSRIs but not SNRIs.
Thus, this does not support the hypothesis that older physi-
cians tend to prescribe drugs that have been available for lon-
ger periods of time. Female physicians were more likely than
male physicians to prescribe SNRIs, and in Germany, were
much less likely to prescribe TCAs. It is unclear why male
and female physicians differ in their prescribing decision mak-
ing. Perhaps surprisingly, physician type was not significantly
associated with antidepressant selection except in Germany,
where PCPs were much more likely to prescribe TCAs than
specialists. Previous studies have not compared factors
72 M. Bauer et al. / European Psychiatry 23 (2008) 66e73influencing antidepressant prescription in the primary care and
specialist settings.
Severity of depression was only associated with the prescrip-
tion of combinations of antidepressants; patients with more se-
vere depression (higher HADS-D score) had a greater likelihood
of receiving a combination of antidepressants than patients with
less severe depression. This is in line with guideline recommen-
dations that combinations of antidepressant medications can be
used for patients with severe depression or treatment-resistant
depression [2,22], although there is little controlled data to
support the utility and efficacy of this strategy [7].
Certain patient socio-demographic characteristics were as-
sociated with the group of antidepressant prescribed at the
baseline visit. Younger patients, non-smokers and those with
further education were more likely to be prescribed SSRIs
vs. other antidepressants. Further research is needed to inves-
tigate why these patient characteristics influence antidepres-
sant prescribing. However, a previous study in the United
States found that younger patients with depression (aged less
than 50 years) were more likely to receive a SSRI or SNRI
than older patients [27].
Antidepressant selection was not influenced by factors such
as current patient functioning (EQ-5D VAS), severity of anxi-
ety (HADS-A score) or comorbidity, except in Germany,
where TCAs were more likely to be prescribed for patients
with more concurrent physical conditions and functional syn-
dromes. In contrast, Zimmerman et al. [38] found that the
presence of comorbid conditions and high levels of anxiety
symptoms influenced antidepressant selection by psychiatrists.
However, the data were collected from only 10 psychiatrists
compared with 437 investigators (211 PCPs and 226 special-
ists) in the present study.4.3. Study strengths and limitationsThe strengths of the FINDER study are that it is a large
study in many European countries and includes samples of
PCPs and specialists who care for patients with depression.
In addition, many patients taking part in the study had comor-
bidities that would have excluded them from randomised con-
trolled trials, but who represent the ‘‘real-world’’ population of
patients with depression [37]. Furthermore, as the treatment
approaches were not dictated by the study protocol, they re-
flect the usual care of depression in routine clinical practice.
Since some investigator characteristics were collected as
well, we included them in our analyses and, by adjusting for
patient characteristics, were able to investigate these pre-
scriber characteristics separately.
This study has several limitations. Firstly, we did not col-
lect any information on patient preferences, an important fac-
tor to consider when prescribing antidepressants [22], and how
this may or may not have influenced the prescribing behaviour
of investigators. Secondly, the patient sample overall and
within each country may not be representative of the patients
treated in an outpatient setting for depression in the respective
country. Moreover, it is likely that investigators participating
in FINDER, especially PCPs, had an interest in depressionas a research area and may, therefore, be better informed about
depression than other investigators who declined to participate
in the study. This may indicate that we have underestimated
the importance of the physician-related associated factors.
5. Conclusions
The prescribing of antidepressants for patients with a clini-
cal diagnosis of depression differs by country and is influenced
by both physician and patient characteristics. Our analysis in-
dicates that the recommendation for previous antidepressant
experience to be taken into account is being largely followed
in routine clinical practice.
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